-DOCSTART- -X- O
The -X- _ O
2014â€“15 -X- _ O
Ebola -X- _ O
outbreak -X- _ O
in -X- _ O
West -X- _ O
Africa -X- _ O
highlighted -X- _ O
the -X- _ O
potential -X- _ O
for -X- _ O
large -X- _ O
disease -X- _ O
outbreaks -X- _ O
caused -X- _ O
by -X- _ O
emerging -X- _ O
pathogens -X- _ O
and -X- _ O
has -X- _ O
generated -X- _ O
considerable -X- _ O
focus -X- _ O
on -X- _ O
preparedness -X- _ O
for -X- _ O
future -X- _ O
epidemics. -X- _ O
Here -X- _ O
we -X- _ O
discuss -X- _ O
drivers -X- _ O
, -X- _ O
strategies -X- _ O
and -X- _ O
practical -X- _ O
considerations -X- _ O
for -X- _ O
developing -X- _ O
vaccines -X- _ O
against -X- _ O
outbreak -X- _ O
pathogens. -X- _ O
Chimpanzee -X- _ B-Intervention
adenoviral -X- _ I-Intervention
( -X- _ I-Intervention
ChAd -X- _ I-Intervention
) -X- _ I-Intervention
vectors -X- _ I-Intervention
have -X- _ O
been -X- _ O
developed -X- _ O
as -X- _ O
vaccine -X- _ O
candidates -X- _ O
for -X- _ O
multiple -X- _ B-Patient
infectious -X- _ I-Patient
diseases -X- _ I-Patient
and -X- _ I-Patient
prostate -X- _ I-Patient
cancer. -X- _ I-Patient
ChAd -X- _ O
vectors -X- _ O
are -X- _ O
safe -X- _ O
and -X- _ O
induce -X- _ B-Outcome
antigen-specific -X- _ I-Outcome
cellular -X- _ I-Outcome
and -X- _ I-Outcome
humoral -X- _ I-Outcome
immunity -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
age -X- _ I-Outcome
groups -X- _ I-Outcome
, -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
circumventing -X- _ I-Outcome
the -X- _ I-Outcome
problem -X- _ I-Outcome
of -X- _ I-Outcome
pre-existing -X- _ I-Outcome
immunity -X- _ I-Outcome
encountered -X- _ I-Outcome
with -X- _ I-Outcome
human -X- _ I-Outcome
Ad -X- _ I-Outcome
vectors. -X- _ I-Outcome
For -X- _ O
these -X- _ O
reasons -X- _ O
, -X- _ O
such -X- _ O
viral -X- _ O
vectors -X- _ O
provide -X- _ O
an -X- _ O
attractive -X- _ O
platform -X- _ O
for -X- _ O
stockpiling -X- _ O
vaccines -X- _ O
for -X- _ O
emergency -X- _ O
deployment -X- _ O
in -X- _ O
response -X- _ O
to -X- _ O
a -X- _ O
threatened -X- _ O
outbreak -X- _ O
of -X- _ O
an -X- _ O
emerging -X- _ O
pathogen. -X- _ O
Work -X- _ O
is -X- _ O
already -X- _ O
underway -X- _ O
to -X- _ O
develop -X- _ O
vaccines -X- _ O
against -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
other -X- _ O
outbreak -X- _ O
pathogens -X- _ O
and -X- _ O
we -X- _ O
will -X- _ O
also -X- _ O
review -X- _ O
progress -X- _ O
on -X- _ O
these -X- _ O
approaches -X- _ O
here -X- _ O
, -X- _ O
particularly -X- _ O
for -X- _ O
Lassa -X- _ O
fever -X- _ O
, -X- _ O
Nipah -X- _ O
and -X- _ O
MERS -X- _ O
. -X- _ O

